9 October 2019
August and September have been landmark months for Smileyscope. We welcome our largest investor to date, and are closing a funding round which will allow us to grow rapidly through the next 18 months. Our product, on the back of our highly successful clinical trial publication in The Journal of Pediatrics, is attracting further interest in Australia and the USA, and we have pilots in other international markets including Dubai and Israel. Smileyscope – the first Virtual Reality device to significantly reduce a child’s pain, distress and need for restraints during blood draws and intravenous cannulation – is becoming established as the market leader.
Lead investor secured
Smileyscope is delighted to announce that we have secured a prominent Silicon Valley investor, a leader in digital health space, as a core investor in the company. We have commitments from an array of other strategically important investors, and will look to close our fundraise in November. Smileyscope’s adoption in hospitals and clinics is expanding rapidly, and our customer waitlist is growing. The new funding will be used to meet this demand, to build and launch two new applications, and to build the company’s capabilities.
Those interested in investing should contact our CEO, Dr Evelyn Chan (+1 917 284 2596 / +61 458 157 405, evelyn@smileyscope.com) directly for more information.
Read the full newsletter here: Smileyscope newsletter
